Edward Fang, MD

Chief Medical Officer
MicuRx Pharmaceuticals Inc

Disclosure(s): MicuRx Pharmaceuticals Inc: Employee

Edward Fang, MD
Chief Medical Officer
MicuRx Pharmaceuticals, Inc
Past: Adenium Biotech, Trius Therapeutics, Cerexa
Experience: More than 15 years in the development of antibacterials for MDR pathogens through all phases of clinical development. Two prior programs with approvals - ceftaroline, tedizolid. Most recently - contezolid and contezolid acefosamil for DFI and ABSSSI.

Poster(s):

• 1699 - Efficacy and Safety by BMI Category and Gender in Contezolid and Contezolid Acefosamil Phase 2 and Phase 3 Skin Infection Clinical Trials
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 1700 - Efficacy and Safety in Subjects with Renal Impairment in Contezolid and Contezolid Acefosamil Phase 2 and Phase 3 Skin Infection Clinical Trials
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 1701 - Pharmacokinetics in Subjects with Renal Impairment in a Contezolid Complicated Skin and Soft Tissue Infection Phase 3 Clinical Trial
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET

• 1702 - Platelet Counts in Contezolid Complicated Skin and Soft Tissue Infection Phase 2 and Phase 3 Clinical Trials
  Saturday, October 22, 2022

  12:15 PM – 1:30 PM US ET